Biotech Values

[DewDiligence]

ADH European Trial of ADH-1
Advances to Phase-2 Portion

[This trial, which enrolled patients with miscellaneous solid tumors during the phase-1b portion, will now be limited to NSCLC and ovarian cancer and will test ADH-1 monotherapy at four times the dose used in the phase-2 North American study, which recently added trial sites (#msg-10402151). A U.S. phase-2 combination trial with chemotherapy is expected to start soon. The NCI is planning to run additional U.S. trials (#msg-10526037).]

http://biz.yahoo.com/iw/060503/0126799.html

>>
Adherex Concludes Phase Ib Component of European ADH-1 Trial, Data to be Presented at 2006 Asco Annual Meeting in June

Wednesday May 3, 9:23 am ET

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(MARKET WIRE)--May 3, 2006 -- Adherex Technologies Inc. (TSX:AHX.TO)(AMEX: ADH ), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that the Company has concluded the Phase Ib component of its Phase Ib/II ADH-1 trial in Europe and has begun the expanded accrual restricted to lung and ovarian cancers. The study, which is examining a weekly dosing schedule of ADH-1, will now enroll patients at the maximum studied dose of 2400 mg/m2 with N-cadherin positive non-small cell lung cancer and ovarian cancer. The Company expects to enroll approximately 20 further patients in this trial. The number of patients enrolled could be increased, depending on the level of anti-tumor activity noted.

The Phase Ib data will be reported at a poster discussion presentation at the 2006 American Society of Clinical Oncology Annual meeting on Saturday, June 3, 2006 from 8 a.m.-1 p.m. being held in Atlanta.

[As previously reported]: Adherex is also studying ADH-1 as a single agent in a Phase II trial at six centers in Canada, with plans for additional sites in the U.S. That trial is examining a weekly dosing schedule of 600 mg/m2 of ADH-1 in patients with one of five N-cadherin positive tumors (lung, liver, esophageal, kidney or adrenocortical). The Company also plans to begin studies of ADH-1 in combination with other anti-cancer agents, such as chemotherapy, radiation therapy or biologics, in mid 2006. A maximum tolerated dose of ADH-1 has not yet been identified.

About Adherex Technologies

Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have multiple products in the clinical stage of development, including ADH-1 (Exherin(TM)), eniluracil and sodium thiosulfate (STS). ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex is emerging as a pioneering oncology company. For more information, please visit our website at www.adherex.com.
<<